REG - Avacta Group PLC - Avacta announces data update for AVA6000

AvactaAnnouncement

07/03/2025 08:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250307:nRSG8110Za&default-theme=true

RNS Number : 8110Z  Avacta Group PLC  07 March 2025

 

 

 

Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the
Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion
Cohorts

 

Encouraging Progression Free Survival (PFS) data observed in patients with
salivary gland cancers compared to conventional treatments

 

 

LONDON AND PHILADELPHIA - 07 March 2025 - Avacta Therapeutics (AIM: AVCT), a
life sciences company developing next generation peptide drug conjugates (PDC)
targeting powerful anti-tumor payloads directly to the tumor, is pleased to
announce that the lead program of the Company, AVA6000, the first clinical
stage asset which is a pre|CISION(®)-enabled form of doxorubicin, has
completed the Phase 1a dose escalation with encouraging PFS data in patients
with salivary gland cancers.

 

The Company has initiated enrollment in the Phase 1b expansion cohorts with
multiple patients treated.

 

Promising early efficacy and safety signals are observed in the Phase 1a
trial. As of the most recent data cut-off, the favorable safety profile
continues to be observed when compared with conventional dose doxorubicin,
including no observed events of severe cardiac toxicity, which are associated
with conventional doxorubicin.

 

Among patients in the dose-escalation portion, 11 patients with salivary gland
cancers have been treated with AVA6000 at or above the dose of 250 mg/m(2) and
above. Among these 11 patients, one patient experienced a confirmed partial
response as best response (greater than -30% reduction in tumor diameters by
RECIST criteria), four patients had minor responses (-10 to -29% reduction by
RECIST criteria), and only one patient had disease progression for a disease
control rate of 91%. These responses have been durable to date. Importantly,
the median PFS has not yet been reached, as five patients remain on AVA6000
treatment and 9 of the 11 patients are without progression and remain in
follow-up. The median time of follow-up in this cohort is approximately 5
months. These data compare very favorably to published PFS reports (with
conventional anti-cancer therapy) in this setting of pre-treated SGC, is
reported at approximately 3.5 months. It is anticipated that PFS would be the
primary endpoint in the registrational trial of AVA6000 in this indication,
which is characterized by low response rates and high unmet need.

 

Avacta also announces patient dosing in the AVA6000 Phase 1b expansion cohorts
with multiple patients treated in this portion of the trial, which include
three indications: (1) salivary gland cancer, (2) triple negative breast
cancer and (3) high grade soft tissue sarcoma.   Each arm of the Phase 1b
expansion cohort will enroll 20-30 patients by the following criteria.

 

·    Salivary gland cancers: patients with advanced or metastatic salivary
gland cancers of any histologic subtype.  Patients may have received up to 1
prior line of therapy in the metastatic or advanced setting.

 

·    Triple negative breast cancer: patients with advanced or metastatic
triple negative breast cancer with up to 2 prior lines of therapy in the
metastatic or advanced setting

 

·    High grade soft tissue sarcomas: patients with undifferentiated
pleomorphic sarcoma or dedifferentiated liposarcoma and patients may have
received 0 or 1 prior line of therapy in the metastatic or advanced setting

 

The Company anticipates providing a further update from the Phase 1a dose
escalation data in 2Q 2025 and Phase 1b dose expansion cohort data at the end
of 2025. The full Phase 1a data will be presented in 2H 2025, including a full
assessment of the cardiac safety data with long-term follow up.  The data
will allow the Company to plan for the registration study of AVA6000.

 

Alan Ho, MD PhD, Chief of the Head and Neck Oncology Service, Memorial Sloan
Kettering Cancer Center and member, Avacta Scientific Advisory Board,
commented:

 

"We are very excited to move the development of AVA6000 to the next level to
generate data that demonstrates clinically meaningful efficacy and
durability of response in patients with previously treated salivary gland
cancers.  It is important to note the high degree of unmet need in this
disease where few agents have shown efficacy.  I am happy to participate in
the trials of AVA6000 in this disease setting going forward."

 

Christina Coughlin, CEO of Avacta Therapeutics commented:

 

"We are very pleased to advance to the expansion cohorts in the AVA6000 trial
in these three indications with high unmet need.  Our development of AVA6000
is proceeding according to plans and today's new data demonstrate the
durability of the responses we have observed in the SGC indication.  We
believe that AVA6000 has an important role to play in the clinic, given our
preliminary efficacy data and the large commercial market size of conventional
doxorubicin"

 

 

 

-Ends-

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                           www.avacta.com (http://www.avacta.com/)

 Michael Vinegrad, Group Communications

 Director

 Peel Hunt (Nomad and Broker)

 James Steel / Chris Golden / Patrick Birkholm              www.peelhunt.com (http://www.peelhunt.com/)

 Panmure Liberum (Joint Broker)                             www.panmureliberum.com (http://www.panmureliberum.com)

 Emma Earl / Will Goode / Mark Rogers

 ICR Healthcare

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert   avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com)

 Investor Contact

 Renee Leck                                                 renee@thrustsc.com (mailto:renee@thrustsc.com)

 THRUST Strategic Communications

 Media Contact

 Carly Scaduto                                              Carly@carlyscadutoconsulting.com

                                                          (https://www.globenewswire.com/Tracker?data=YG-jwixFWaHByFwlhEr4NbVmhGc9YbrV0ozbiHY-33jDG-KDtaZDvqBLS4-5RgIi5zejtwvrLPO1U6xSYlV9BnK-dIegbuZft6wwj-ugstEWYrPDSrd9NwgKYBdm1l9Ty6VSa1gsRJqxeLaMfUN-easXzPVocBafm0xbzTKFahId-T7w4WgPYGYfKdFh6MGXNNniX0b0LrpQwjqHYj_mTmjerN3nRW6pwlbWejQ6wZCns0oke-U-WA7CB-Z2CD1ObedcWrqwKYgQwTY1NxAOLXtmHTL3VJ7HZ4Z3K9ZhB_2_vgbo4aKKTppE6l1bjU2w)
 Carly Scaduto Consulting

 

 

About Avacta - www.avacta.com
(https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.avacta.com%2F&data=05%7C02%7CChris.Coughlin%40avacta.com%7Ce5faa8dfbe3d49fc56f808dd35799958%7C64d2165ff9e04869bc73bfe4fc4fa9ab%7C0%7C0%7C638725518576703790%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=qWTC74zmTzjVQqwaFiKeiHUwMY5RUlsvb7C%2BkLRahGU%3D&reserved=0)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary payload delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent payloads in the tumor microenvironment
while sparing normal tissues. Our innovative pipeline consists of
pre|CISION(®) peptide drug conjugates (PDC) or Affimer(®) drug conjugates
(AffDC) that leverage the tumor-specific release mechanism, providing unique
benefits over traditional antibody drug conjugates.

 

About the pre|CISION(®) Platform

The pre|CISION(®) platform comprises an anticancer payload conjugated to a
proprietary peptide that is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumors compared
with healthy tissues. The pre|CISION(®) platform harnesses this tumor
specific protease to cleave pre|CISION(®) peptide drug conjugates and
pre|CISION(®) antibody/Affimer(®) drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and reducing
systemic exposure and toxicity, allowing dosing to be optimized to deliver the
best outcomes for patients.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGIGDXRXGDGUR